We are live on ! Find out more
KXA

KPCB XIII Associates Portfolio holdings

AUM $186M
1-Year Est. Return 11.23%
This Fund
S&P 500
This Quarter Est. Return
+23.86%
1 Year Est. Return
-11.23%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$224M
AUM Growth
-$2.38M
Cap. Flow
-$50.5M
Cap. Flow %
-22.57%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PGNY icon
Progyny
PGNY
+$50.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.06%
2 Technology 4.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PGNY icon
1
Progyny
PGNY
$2.46B
$200M 89.23%
5,074,615
-1,398,900
-22% -$50.5M
LUNG icon
2
Pulmonx
LUNG
$51.1M
$13M 5.83%
994,971
MVLA
3
DELISTED
Movella Holdings Inc. Common Stock
MVLA
$11.1M 4.94%
5,189,011

Similar funds

KPCB XIII Associates's Q2 2023 Portfolio in Review

As of Q2 2023, KPCB XIII Associates held 3 positions worth $224M, down 1.1% from $226M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

KPCB XIII Associates withdrew a net $50.5M in Q2 2023, reducing 1 holding. Its largest reduction was Progyny, cutting an estimated $50.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Technology.

  • KPCB XIII Associates's biggest Q2 2023 reduction was Progyny, cutting an estimated $50.5M.
  • KPCB XIII Associates's ten largest holdings make up 100% of its $224M portfolio in Q2 2023.
  • KPCB XIII Associates opened 0 new positions and closed 0 in Q2 2023.
  • KPCB XIII Associates's portfolio value fell 1.1% quarter-over-quarter to $224M.

Based on KPCB XIII Associates's 13F filing for Q2 2023, filed 8 Aug 2023.